New XFG COVID-19 variant part of natural evolution of SARS-CoV-2: Former ICMR chief Dr Bhargava
Dr Bhargava
was part of the team at the forefront of managing the country's response to the COVID-19 pandemic.
"The emergence of the XFG variant is part of the SARS-CoV-2 virus's natural evolution," he said.
His statement comes as India's active COVID-19 cases crossed 7,000 as of June 11, with over 300 added in the last 24 hours and six deaths recorded in the same period, data from the Union Health Ministry shows.
According to the latest data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), 206 cases have been linked to XFG variant, with the highest count of 89 infections coming from Maharashtra, followed by West Bengal reporting 49.
Dr Bhargava said the XFG variant of SARS-CoV-2 (which causes COVID-19) carries mutations which may improve its ability of binding to human cells and bypassing immune defences.
"Early reports suggest that the variant has high
immune escape potential
, but there is no current evidence to indicate (an) increased severity (of disease)," he said.
Other states reporting infections due to the XFG variant are Kerala (15), Tamil Nadu (16), Gujarat (11), Madhya Pradesh (6), Andhra Pradesh (6), Odisha (4), Puducherry (3), Delhi (2), Rajasthan (2), and Punjab, Telangana and Haryana (one each).
However, similar to how the virus adapts, so has India's diagnostic infrastructure since the first wave of the pandemic, and the RT-PCR test, or 'reverse transcription-polymerase chain reaction' -- which detects the genetic material of SARS-CoV-2 in samples -- remains its cornerstone, the cardiologist said.
He added that the widespread deployment of platforms such as Truenat -- a rapid molecular diagnostic test that uses RT-PCR technology for diagnosis -- puts India in a strong position to detect and contain emerging variants swiftly, even in remote and resource-limited settings.
Point-of-care testing, which detects antibodies in blood, played a crucial role during the pandemic then, and it continues to be a frontline tool for detecting emerging variants, such as XFG, Dr Bhargava said.
"Vigilance is critical now, and not panic. As we have done in the past, we should continue testing when symptomatic, masking in crowded spaces, and staying up to date with vaccinations", he said.
India has seen 74 deaths in the current surge in COVID-19 cases, which started January this year. Kerala continues to be the most affected with over 2,200 cases, followed by Gujarat (1223) and Delhi (757).
Official sources have said that most cases are mild and can be managed under home care, even as all states have been instructed to ensure availability of oxygen, isolation beds, ventilators, and essential medicines, amidst rising cases of COVID-19.
INSACOG data also shows that 21 of the newly emerging cases are linked to the LF.7 variant -- Maharashtra and Gujarat reporting the highest with six cases each -- and two to the NB.1.8.1 variant -- one each in Maharashtra and Tamil Nadu. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
27 minutes ago
- NDTV
Raghav Chadha Says Annual Health Checkups A "Luxury", Should Be For All
New Delhi: Aam Aadmi Party (AAP) Rajya Sabha MP Raghav Chadha on Monday demanded that every citizen be granted a legal right to Annual Health Checkups, highlighting that the early diagnosis of diseases could save countless lives and ease the burden on India's healthcare system. During a Special Mention in the Upper House, Mr Chadha said, "Annual health checkups have become a luxury in our country - something only the affluent can afford. A mother who never knew she had cancer, a son who discovered his blood pressure only after a stroke, a sister whose vision loss revealed diabetes - these stories are far too common." Referring to the aftermath of the Covid-19 pandemic and several viral videos of young people suffering cardiac arrests on a daily basis, Mr Chadha said the time has come for structured, state-sponsored preventive healthcare becoming central to India's public health policy. Mr Chadha said that only 2 per cent of Indian women have undergone cancer screening, citing data from the National Family Health Survey (NFHS-5), terming it "deeply alarming." He urged the government to make affordable, accessible and routine health screenings a legal right for every citizen, with systems in place across urban and rural India. "In several countries, governments proactively conduct health checkups. They invite citizens to participate and ensure that illnesses are caught early," Mr Chadha said in Parliament. Speaking to NDTV after raising the issue in Parliament, Mr Chadha said, "This is standard practice in most developed countries, but sadly not in India. If the government allows this, I don't think it will be a huge financial burden." He added, "In fact, it will actually bring healthcare expenditure down in the long run. When illnesses are detected early, we avoid the need for prolonged and costly treatments in government hospitals." A study published in the Lancet journal found that around 55 per cent of heart attack deaths in India occur due to delays in seeking timely diagnosis. Mr Chadha concluded by saying, "Jaan hai, toh janch hai. But janch hogi, tabhi toh jaan bachegi (If there is life, then there is a diagnosis. But lives can only be saved if there is a diagnosis)."
News18
5 hours ago
- News18
Indo-US Earth Radar Mission: NISAR To Finally Lift-Off From Sriharikota On July 30
NISAR has been nearly a decade in the making, with scientists from both India and the United States meticulously developing two scientific payloads for the powerful satellite After a long delay, the much-anticipated Indo-US joint satellite mission, NISAR, is set to launch from Sriharikota at 5:40 pm on July 30, the Indian Space Research Organization (ISRO) confirmed on Monday. The mission will deploy one of the largest and most advanced radar systems in space to provide an unprecedented view of the Earth. The satellite will lift-off on a GSLV-F16 from Satish Dhawan Space Centre in Sriharikota, and inject it into a 743 km Sun-synchronous orbit with an inclination of 98.4 degrees. Weighing nearly 2392 kg, the NASA-ISRO Synthetic Aperture Radar (NISAR) has been developed jointly by scientists from ISRO as well as NASA. NISAR has been nearly a decade in the making, with scientists from both India and the United States meticulously developing the mission's two scientific payloads — even through the challenges posed by the Covid-19 pandemic. While NASA developed the L-band radar for longer-wavelength imaging, ISRO and the Space Applications Centre (SAC) in Ahmedabad built the complementary S-band radar. It is the first satellite to observe the Earth with a dual frequency synthetic aperture radar both using NASA's 12-metre unfurlable mesh reflector antenna integrated to ISRO's modified 13K satellite bus. The powerful satellite will observe Earth with a swath of 242 km and provide high-resolution imagery using SweepSAR technology for the first time, said the space agency. It will scan the entire globe and provide all weather, day and night data at an interval of 12 days. It can even detect small changes in the Earth's surface, any deformation, movement of ice sheets and loss of vegetation. According to the space agency, NISAR will enable a wide range of applications, and help in studies which require classification of sea ice, monitoring of shorelines, changes in soil moisture, mapping and monitoring of surface water resources, as well as characterising storms, and detecting ships in the sea. This will also help in streamlining early disaster response, said ISRO. Initially scheduled for an early 2024 launch, the mission has faced multiple delays after one of its components had to be sent back to the US for corrections. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
Sun Pharmaceutical Industries has announced that its psoriasis drug ILUMYA (tildrakizumab 100 mg) delivered positive results in two late-stage clinical trials for active psoriatic arthritis (PsA), potentially paving the way for regulatory filings in the United States. The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24. INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose. Consistent safety profile supports regulatory case Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified. ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities. Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals. Targeting IL-23 in chronic inflammatory pathways ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk. Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed. Strategic pipeline strengthens global presence Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
